Preventive therapy for cancer

Bisgaard, 1994, Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate, Hum Mutat, 3, 121, 10.1002/humu.1380030206 Half, 2009, Familial adenomatous polyposis, Orphanet J Rare Dis, 4, 22, 10.1186/1750-1172-4-22 Mavaddat, 2013, Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J Natl Cancer Inst, 105, 812, 10.1093/jnci/djt095 Guillem, 2006, ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes, J Clin Oncol, 24, 4642, 10.1200/JCO.2005.04.5260 Ludwig, 2016, Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review, Am J Surg, 212, 660, 10.1016/j.amjsurg.2016.06.010 Dubeau, 2008, The cell of origin of ovarian epithelial tumours, Lancet Oncol, 9, 1191, 10.1016/S1470-2045(08)70308-5 Southey, 2016, PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS, J Med Genet, 53, 800, 10.1136/jmedgenet-2016-103839 Ault, 2007, Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials, Lancet, 369, 1861, 10.1016/S0140-6736(07)60852-6 Paavonen, 2009, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, Lancet, 374, 301, 10.1016/S0140-6736(09)61248-4 Joura, 2015, A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women, N Engl J Med, 372, 711, 10.1056/NEJMoa1405044 Chang, 2016, Long-term effects of hepatitis B immunization of infants in preventing liver cancer, Gastroenterology, 151, 472, 10.1053/j.gastro.2016.05.048 Fung, 2009, Hepatitis B and C virus-related carcinogenesis, Clin Microbiol Infect, 15, 964, 10.1111/j.1469-0691.2009.03035.x Webster, 2015, Hepatitis C, Lancet, 385, 1124, 10.1016/S0140-6736(14)62401-6 Havrilesky, 2013, Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis, Obstet Gynecol, 122, 139, 10.1097/AOG.0b013e318291c235 Cuzick, 2014, Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial, Lancet, 383, 1041, 10.1016/S0140-6736(13)62292-8 Rothwell, 2010, Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet, 376, 1741, 10.1016/S0140-6736(10)61543-7 Algra, 2012, Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials, Lancet Oncol, 13, 518, 10.1016/S1470-2045(12)70112-2 Bosetti, 2012, Aspirin and cancer risk: a quantitative review to 2011, Ann Oncol, 23, 1403, 10.1093/annonc/mds113 Cuzick, 2013, Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data, Lancet, 381, 1827, 10.1016/S0140-6736(13)60140-3 Martino, 2004, Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst, 96, 1751, 10.1093/jnci/djh319 Barrett-Connor, 2006, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women, N Engl J Med, 355, 125, 10.1056/NEJMoa062462 Vogel, 2006, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial, JAMA, 295, 2727, 10.1001/jama.295.23.joc60074 LaCroix, 2010, Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women, J Natl Cancer Inst, 102, 1706, 10.1093/jnci/djq415 Powles, 2012, Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene, Breast Cancer Res Treat, 134, 299, 10.1007/s10549-012-2041-5 Goss, 2011, Exemestane for breast-cancer prevention in postmenopausal women, N Engl J Med, 364, 2381, 10.1056/NEJMoa1103507 1988, Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer, Br J Cancer, 57, 604, 10.1038/bjc.1988.137 Cuzick, 1985, Tamoxifen and contralateral breast cancer, Lancet, 2, 282, 10.1016/S0140-6736(85)90338-1 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0 Powles, 2007, Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial, J Natl Cancer Inst, 99, 283, 10.1093/jnci/djk050 Cuzick, 2015, Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial, Lancet Oncol, 16, 67, 10.1016/S1470-2045(14)71171-4 Fisher, 2005, Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study, J Natl Cancer Inst, 97, 1652, 10.1093/jnci/dji372 Veronesi, 2007, Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy, J Natl Cancer Inst, 99, 727, 10.1093/jnci/djk154 Cuzick, 2010, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol, 11, 1135, 10.1016/S1470-2045(10)70257-6 Sestak, 2009, Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial, J Clin Oncol, 27, 4961, 10.1200/JCO.2009.22.0236 Spagnolo, 2016, Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II Prevention trial, J Clin Oncol, 34, 139, 10.1200/JCO.2015.63.4972 Thorat, 2015, Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population, Eur J Epidemiol, 30, 5, 10.1007/s10654-014-9971-7 Cuzick, 2007, Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial, J Natl Cancer Inst, 99, 272, 10.1093/jnci/djk049 Lee, 2016, Novel routes for administering chemoprevention: local transdermal therapy to the breasts, Semin Oncol, 43, 107, 10.1053/j.seminoncol.2015.09.003 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial, JAMA, 282, 637, 10.1001/jama.282.7.637 Cauley, 2001, Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation, Breast Cancer Res Treat, 65, 125, 10.1023/A:1006478317173 Cummings, 2010, Lasofoxifene in postmenopausal women with osteoporosis, N Engl J Med, 362, 686, 10.1056/NEJMoa0808692 Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J Clin Oncol, 28, 509, 10.1200/JCO.2009.23.1274 Cuzick, 2005, Aromatase inhibitors for breast cancer prevention, J Clin Oncol, 23, 1636, 10.1200/JCO.2005.11.027 Cuzick, 2015, Estimates of benefits and harms of prophylactic use of aspirin in the general population, Ann Oncol, 26, 47, 10.1093/annonc/mdu225 Baandrup, 2015, Low-dose aspirin use and the risk of ovarian cancer in Denmark, Ann Oncol, 26, 787, 10.1093/annonc/mdu578 Rothwell, 2011, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials, Lancet, 377, 31, 10.1016/S0140-6736(10)62110-1 Rothwell, 2012, Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials, Lancet, 379, 1591, 10.1016/S0140-6736(12)60209-8 Cook, 2013, Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial, Ann Intern Med, 159, 77, 10.7326/0003-4819-159-2-201307160-00002 1989, Final report on the aspirin component of the ongoing Physicians' Health Study, N Engl J Med, 321, 129, 10.1056/NEJM198907203210301 Mills, 2012, Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials, Am J Med, 125, 560, 10.1016/j.amjmed.2012.01.017 Chan, 2009, Aspirin use and survival after diagnosis of colorectal cancer, JAMA, 302, 649, 10.1001/jama.2009.1112 Holmes, 2010, Aspirin intake and survival after breast cancer, J Clin Oncol, 28, 1467, 10.1200/JCO.2009.22.7918 Langley, 2011, Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?, Br J Cancer, 105, 1107, 10.1038/bjc.2011.289 Chubak, 2016, Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services task force, Ann Intern Med, 164, 814, 10.7326/M15-2117 Chan, 2005, Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer, JAMA, 294, 914, 10.1001/jama.294.8.914 Shebl, 2014, Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study, PLoS One, 9, e114633, 10.1371/journal.pone.0114633 Bodmer, 2010, Long-term metformin use is associated with decreased risk of breast cancer, Diabetes Care, 33, 1304, 10.2337/dc09-1791 Zhang, 2016, Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis, Gynecol Oncol, 142, 368, 10.1016/j.ygyno.2016.04.543 Golozar, 2016, Does metformin reduce cancer risks? Methodologic considerations, Curr Diab Rep, 16, 4, 10.1007/s11892-015-0697-z Gandini, 2014, Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders, Cancer Prev Res, 7, 867, 10.1158/1940-6207.CAPR-13-0424 Pollak, 2010, Metformin and other biguanides in oncology: advancing the research agenda, Cancer Prev Res, 3, 1060, 10.1158/1940-6207.CAPR-10-0175 Naithani, 2008, Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials, Curr Med Chem, 15, 1044, 10.2174/092986708784221403 Szabo, 2015, Biomarkers in phase I–II chemoprevention trials: lessons from the NCI experience, Ecancermedicalscience, 9, 599, 10.3332/ecancer.2015.599 Negri, 1991, Vegetable and fruit consumption and cancer risk, Int J Cancer, 48, 350, 10.1002/ijc.2910480307 Lenzi, 2014, Sulforaphane as a promising molecule for fighting cancer, Cancer Treat Res, 159, 207, 10.1007/978-3-642-38007-5_12 Mills, 1989, Cohort study of diet, lifestyle, and prostate cancer in Adventist men, Cancer, 64, 598, 10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6 Key, 2015, Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies, Am J Clin Nutr, 102, 1142, 10.3945/ajcn.115.114306 Zheng, 2016, Spices for prevention and treatment of cancers, Nutrients, 8, E495, 10.3390/nu8080495 Devassy, 2015, Curcumin and cancer: barriers to obtaining a health claim, Nutr Rev, 73, 155, 10.1093/nutrit/nuu064 Hackshaw-McGeagh, 2015, A systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate cancer progression and mortality, Cancer Causes Control, 26, 1521, 10.1007/s10552-015-0659-4 Vang, 2011, What is new for an old molecule? Systematic review and recommendations on the use of resveratrol, PLoS One, 6, e19881, 10.1371/journal.pone.0019881 Gescher, 2013, Resveratrol in the management of human cancer: how strong is the clinical evidence?, Ann N Y Acad Sci, 1290, 12, 10.1111/nyas.12205 Li, 2014, Green tea compounds in breast cancer prevention and treatment, World J Clin Oncol, 5, 520, 10.5306/wjco.v5.i3.520 Malik, 2005, Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer, Proc Natl Acad Sci USA, 102, 14813, 10.1073/pnas.0505870102 Bjelakovic, 2014, Vitamin D supplementation for prevention of cancer in adults, Cochrane Database Syst Rev, 6 2008 Sporn, 1976, Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids), Fed Proc, 35, 1332 Peto, 1981, Can dietary beta-carotene materially reduce human cancer rates?, Nature, 290, 201, 10.1038/290201a0 Blot, 1993, Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease specific mortality in the general population, J Natl Cancer Inst, 85, 1483, 10.1093/jnci/85.18.1483 Omenn, 1996, Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease, N Engl J Med, 334, 1150, 10.1056/NEJM199605023341802 Albanes, 1996, Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance, J Natl Cancer Inst, 88, 1560, 10.1093/jnci/88.21.1560 Druesne-Pecollo, 2010, Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials, Int J Cancer, 127, 172, 10.1002/ijc.25008 Klein, 2011, Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 306, 1549, 10.1001/jama.2011.1437 Jiang, 2010, Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: a meta-analysis of randomized controlled trials, Nutr Cancer, 62, 719, 10.1080/01635581.2010.494335 Pais, 2013, Do antioxidants prevent colorectal cancer? A meta-analysis, Rom J Intern Med, 51, 152 Bjelakovic, 2012, Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases, Cochrane Database Syst Rev, 3 Thompson, 2013, Long-term survival of participants in the prostate cancer prevention trial, N Engl J Med, 369, 603, 10.1056/NEJMoa1215932 Andriole, 2010, Effect of dutasteride on the risk of prostate cancer, N Engl J Med, 362, 1192, 10.1056/NEJMoa0908127 Pinsky, 2013, Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials, Cancer, 119, 593, 10.1002/cncr.27774 Emberson, 2012, Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy, PLoS One, 7, e29849, 10.1371/journal.pone.0029849 Parkin, 2011, The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010, Br J Cancer, 105, S77, 10.1038/bjc.2011.489 2002, Weight control and physical activity, vol 6, 60 Thun, 2012, The role of aspirin in cancer prevention, Nat Rev Clin Oncol, 9, 259, 10.1038/nrclinonc.2011.199 Tyrer, 2004, A breast cancer prediction model incorporating familial and personal risk factors, Stat Med, 23, 1111, 10.1002/sim.1668 Gail, 1989, Projecting individualized probabilities of developing breast cancer for white females who are being examined annually, J Natl Cancer Inst, 81, 1879, 10.1093/jnci/81.24.1879 McCormack, 2006, Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis, Cancer Epidemiol Biomarkers Prev, 15, 1159, 10.1158/1055-9965.EPI-06-0034 Brentnall, 2014, Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK, Br J Cancer, 110, 827, 10.1038/bjc.2013.747 Cuzick, 2011, Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study, J Natl Cancer Inst, 103, 744, 10.1093/jnci/djr079 Nyante, 2015, Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer, J Natl Cancer Inst, 107, dju425, 10.1093/jnci/dju425